glp-1-directed nmda receptor antagonism for obesity treatment GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys: Cell Reports Medicine A metabolic balance of GLP-1

The FDA and EMA approvals of ZepBound in late 2023 and early 2024 (for weight management) were major regulatory milestones achieved by Lilly ahead of many competitors

Most GLP-1 agonists have defined titration schedules based on clinical trial data

Early GLP-1 side effects may temporarily impair sleep In the early weeks of treatment, GLP-1 medications can disrupt sleep for some patients

A registered dietitian can help a person assess how much phosphorus they consume and create a suitable eating plan

Theyve been around for nearly 20 years and are intended only for the treatment of specific medical conditions

Eine mgliche therapeutische Wirkung bei Typ-2-Diabetes (T2D) wurde jedoch widerlegt: Whrend GIP bei gesunden Menschen bei moderater Hyperglykmie die Insulinsekretion deutlich stimulierte, war die Wirkung bei Personen mit T2D erheblich abgeschwcht (5)